newsfilter
← Latest News
GlobeNewswire·

U.S. FDA Clears Pluristem’s IND Application for Phase II COVID-19 Study

140 patients with severe COVID-19 and ARDS to be treatedPrimary endpoint: ventilator free days during the main 28-day study period, secondary endpoint includes survival rate and ICU free days HAIFA,...